Daiwa Capital Markets Issues Positive Forecast for Johnson & Johnson (NYSE:JNJ) Stock Price

Johnson & Johnson (NYSE:JNJ) had its price target boosted by stock analysts at Daiwa Capital Markets from $203.00 to $237.00 in a report released on Thursday,MarketScreener reports. The firm presently has an “outperform” rating on the stock. Daiwa Capital Markets’ target price would suggest a potential upside of 4.81% from the company’s previous close.

Several other research firms have also recently commented on JNJ. Wolfe Research boosted their price objective on shares of Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a research report on Monday, January 5th. Morgan Stanley set a $262.00 price target on Johnson & Johnson and gave the stock an “overweight” rating in a research report on Wednesday. TD Cowen lifted their price objective on shares of Johnson & Johnson from $222.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. Raymond James Financial lifted their price target on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research note on Wednesday, October 15th. Finally, Citigroup raised their price objective on Johnson & Johnson from $232.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $231.91.

Johnson & Johnson Price Performance

Shares of JNJ traded down $1.16 during mid-day trading on Thursday, hitting $226.13. 499,658 shares of the company traded hands, compared to its average volume of 9,024,039. The stock has a market capitalization of $544.81 billion, a price-to-earnings ratio of 20.50, a PEG ratio of 2.21 and a beta of 0.34. Johnson & Johnson has a one year low of $141.50 and a one year high of $230.00. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The business has a 50-day moving average of $210.25 and a 200 day moving average of $190.83.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 21st. The company reported $2.46 EPS for the quarter, hitting analysts’ consensus estimates of $2.46. The firm had revenue of $24.56 billion during the quarter, compared to analyst estimates of $24.14 billion. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The company’s revenue was up 9.1% on a year-over-year basis. During the same period last year, the company earned $2.04 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. As a group, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Institutional Trading of Johnson & Johnson

Several institutional investors have recently added to or reduced their stakes in the company. Abich Financial Wealth Management LLC bought a new stake in Johnson & Johnson in the 3rd quarter valued at about $26,000. Evolution Wealth Management Inc. bought a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $27,000. Clayton Financial Group LLC bought a new position in Johnson & Johnson during the 3rd quarter worth $28,000. DecisionPoint Financial LLC raised its holdings in Johnson & Johnson by 104.2% in the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock valued at $30,000 after acquiring an additional 75 shares in the last quarter. Finally, Family CFO Inc acquired a new position in Johnson & Johnson in the fourth quarter valued at about $31,000. 69.55% of the stock is currently owned by institutional investors.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: CHMP gives positive opinion on AKEEGA (niraparib + abiraterone) for BRCA1/2 mHSPC — a potential new standard-of-care that expands J&J’s oncology franchise and supports longer-term revenue upside. Article Title
• Positive Sentiment: Morgan Stanley upgraded JNJ on improved growth outlook; multiple outlets report the upgrade and the stock reaction — analyst upgrades are driving buying interest and helped push JNJ toward a fresh annual peak. Article Title
• Positive Sentiment: Scotiabank raised its price target to $265 (from $230) after a strong quarter and reiterated Outperform — further analyst target lifts add credibility to the rally. Article Title
• Positive Sentiment: US judge dismissed a lawsuit alleging J&J committed fraud over use of a shell-company bankruptcy related to talc litigation — removes a legal overhang and lowers tail risk for investors. Article Title
• Neutral Sentiment: Q4 results: J&J met EPS, beat revenue and gave FY2026 EPS guidance (11.43–11.63) and sales guidance ~ $100–101B — fundamentals support the re-rating but some analysts still view upside as measured. Article Title
• Neutral Sentiment: Options volume is unusually high — can signal elevated speculative/hedge activity but not a directional catalyst by itself. Article Title
• Negative Sentiment: JNJ CEO Joaquin Duato sold ~$22M of stock post-Q4 — large insider sales can spook traders even if filings show routine diversification; worth monitoring for follow-up. Article Title
• Neutral Sentiment: Positive mentions from fund managers and analyst blogs (Barron’s, Zacks, Seeking Alpha) add investor interest but are reiterative rather than new fundamental news. Article Title

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.